This program aims to deliver a functional CFTR gene directly into the lung cells of people with cystic fibrosis using a cutting-edge approach, allowing the lung cells to create normally functioning CFTR protein. This approach has the potential to provide a treatment for all people living with CF, regardless of mutation.
Status
Laboratory studies to develop and test this potential therapy are underway.
Sponsor
This program is sponsored by Carbon Biosciences and partially funded by the Cystic Fibrosis Foundation.
